| P50 | author | Ralf Gold | Q99630149 |
| P2093 | author name string | Jan Thöne | |
| P2860 | cites work | Laquinimod (ABR-215062) suppresses the development of experimental autoimmune encephalomyelitis, modulates the Th1/Th2 balance and induces the Th3 cytokine TGF-beta in Lewis rats | Q45090895 |
| | Cytochrome P450 3A4 is the major enzyme responsible for the metabolism of laquinimod, a novel immunomodulator | Q46375399 |
| | Multiple sclerosis | Q28299151 |
| | Oral laquinimod therapy in relapsing multiple sclerosis | Q33467515 |
| | Treatment with laquinimod reduces development of active MRI lesions in relapsing MS. | Q34405210 |
| | Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study. | Q34788240 |
| | From genes to function: the next challenge to understanding multiple sclerosis | Q37483492 |
| | New drug therapies for multiple sclerosis. | Q37736234 |
| | Oral laquinimod in patients with relapsing-remitting multiple sclerosis: 36-week double-blind active extension of the multi-centre, randomized, double-blind, parallel-group placebo-controlled study | Q42909983 |
| | Laquinimod interferes with migratory capacity of T cells and reduces IL-17 levels, inflammatory demyelination and acute axonal damage in mice with experimental autoimmune encephalomyelitis | Q42946709 |
| | Laquinimod suppress antigen presentation in relapsing-remitting multiple sclerosis: in-vitro high-throughput gene expression study | Q43116803 |
| | Suppression of experimental autoimmune neuritis by ABR-215062 is associated with altered Th1/Th2 balance and inhibited migration of inflammatory cells into the peripheral nerve tissue | Q43977414 |
| | The new orally active immunoregulator laquinimod (ABR-215062) effectively inhibits development and relapses of experimental autoimmune encephalomyelitis | Q44133715 |
| | Synthesis and biological evaluation of new 1,2-dihydro-4-hydroxy-2-oxo-3-quinolinecarboxamides for treatment of autoimmune disorders: structure-activity relationship | Q44823676 |
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | multiple sclerosis | Q8277 |
| | relapsing-remitting multiple sclerosis | Q18555066 |
| P304 | page(s) | 365-370 | |
| P577 | publication date | 2011-02-10 | |
| P1433 | published in | Expert Opinion on Drug Metabolism & Toxicology | Q5421205 |
| P1476 | title | Laquinimod: a promising oral medication for the treatment of relapsing-remitting multiple sclerosis | |
| P478 | volume | 7 | |